Efficacy of Shallakyadi capsule in the prevention of post chikungunya chronic inflammatory rheumatism
Phase 4
Completed
- Conditions
- Health Condition 1: M148- Arthropathies in other specified diseases classified elsewhere
- Registration Number
- CTRI/2020/02/023123
- Lead Sponsor
- Institute for Post Graduate Teaching and Research in Ayurveda Gujarat Ayurved University Jamnagar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
Age between 18 years to 60 years of either sex.
Confirm case of Chikungunya fever
Patient willing to participate in the trial.
Exclusion Criteria
Age below 18 years & above 60 years.
? Pregnant and lactating women
? History of RA, Gout, Psoriatic arthritis, rheumatic fever, autoimmune disease, thyroid
dysfunction, sarcoidosis, SLE before Chikungunya fever.
? Patients suffering from: Malignant and accelerated hypertension, coronary artery
disease, uncontrolled diabetes.
? Patient undergoing regular treatment for any other severe illness and also patients
suffering from pulmonary tuberculosis or bone tuberculosis, carcinoma and HIV positive
patients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method It is expected that the trial drug will reduce the inflammation and pain <br/ ><br>through correcting underlined pathogenesis and so that it will become possible to prevent <br/ ><br>Post-Chikungunya Chronic Inflammatory Rheumatism (pCHIK-CIR).Timepoint: at the end of 8 weeks
- Secondary Outcome Measures
Name Time Method The drug will improve the quality of life in patient of Chikungunya.Timepoint: 8 weeks